ANGPT2 and wet macular degeneration: In the pathologic phase of macular neovascularisation (MNV) in wet AMD (wAMD), angiopoietin-2 (Ang-2) expression increases in the vascular endothelium; this competitively inhibits angiopoietin-1 (Ang-1) from binding tyrosine kinase immunoglobulin-like receptors (Tie 2) on the surface of vascular endothelial cells, thus preventing Ang-1/Tie 2 signalling and resulting in capillary inflammation or pericyte loss4.